Guidelines outline antimicrobial treatment and prophylaxis recommendations for human plague

This guideline document provides recommendations for antimicrobial treatment and prophylaxis of human plague. The population addressed includes humans with naturally acquired plague infections or those potentially exposed following a bioterrorism attack. No specific study type, phase, sample size, setting, or follow-up duration is reported.

No intervention details, comparators, primary or secondary outcomes, or main results with exact numbers are provided. The document focuses on outlining recommended best practices rather than presenting original research findings. Safety and tolerability information, including adverse events, serious adverse events, and discontinuation rates, are not reported.

Key limitations include the absence of reported study methodology, results data, safety information, and funding or conflict of interest disclosures. The practice relevance is that this guideline provides recommended best practices for treatment and prophylaxis of human plague. Clinicians should interpret these recommendations as guidance documents rather than evidence from new clinical studies.